Page last updated: 2024-12-05

phosphoadenosine phosphosulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phosphoadenosine Phosphosulfate: 3'-Phosphoadenosine-5'-phosphosulfate. Key intermediate in the formation by living cells of sulfate esters of phenols, alcohols, steroids, sulfated polysaccharides, and simple esters, such as choline sulfate. It is formed from sulfate ion and ATP in a two-step process. This compound also is an important step in the process of sulfur fixation in plants and microorganisms. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3'-phospho-5'-adenylyl sulfate : An adenosine bisphosphate having monophosphate groups at the 3'- and 5'-positions and a sulfo group attached to the phosphate at position 5'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10214
CHEBI ID17980
SCHEMBL ID238789
MeSH IDM0016656

Synonyms (58)

Synonym
3-phosphoadenosine 5'-phosphosulfate
brn 0073511
adenosine, 3',5'-diphosphate, 5'-anhydride with sulfuric acid
gtpl1719
adenosine-3'-phosphate-5' -phosphosulfate
phosphoadenosine phosphosulfate (paps)
3'-o-phosphono-5'-adenylyl sulfate
CHEBI:17980
adenosine, 3',5'-bis(dihydrogen phosphate), 5'-monoanhydride with sulfuric acid
5'-adenylyl sulfate 3'-phosphate
adenosine 3'-phosphate 5'-sulfatophosphate
adenosine 5'-phosphosulfate 3'-phosphate
5-phosphoadenosine 3-phosphosulfate
3'-phosphate-adenosine-5'-phosphate sulfate
3'-adenylic acid, 5'-(dihydrogen phosphate), 5'-anhydride with sulfuric acid (9ci)
adenosine, 3',5'-bis(dihydrogen phosphate), 5'-monoanhydride with sulfuric acid (8ci)
9h-purin-6-amine, 9-[5-o-[hydroxy(sulfooxy)phosphinyl]-3-o-phosphono-beta-d-ribofuranosyl]-
paps (nucleotide)
adenosine 3',5'-diphosphate, 5'-anhydride with sulfuric acid
3'-adenylic acid, 5'-(dihydrogen phosphate), 5'-anhydride with sulfuric acid
adenosine, 5'-o-[hydroxy(sulfooxy)phosphinyl]-, 3'-(dihydrogen phosphate)
adenosine 3',5'-diphosphate, 5'-anhydride with sulfuric acid (6ci)
482-67-7
3'-phosphoadenylyl sulfate
3'-phospho-5'-adenylyl sulfate
3'-phosphoadenosine 5'-phosphosulfate
PAPS ,
phosphoadenosine phosphosulfate
3'-phosphoadenylyl-sulfate
3'-phosphoadenosine-5'-phosphosulfate
C00053
a3p5ps
1BUX
DB02902
[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methyl sulfo hydrogen phosphate
3'-phosphoadenosine-5'-phosphosulfate, [35s]
5th3erg159 ,
4-26-00-03662 (beilstein handbook reference)
unii-5th3erg159
SCHEMBL238789
[({[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]sulfonic acid
J-002280
adenosine 3'-phosphate 5'-phosphosulfate lithium salt
GACDQMDRPRGCTN-KQYNXXCUSA-N
3'-phosphoadenosin-5'-phosphosulfat
3'-phosphoadenosine-5'-phosphosulphate
3'-phosphoadenylyl-sulphate
3'-phospho-5'-adenylyl sulphate
phosphoadenosine phosphosulphate
5-phosphoadenosine 3-phosphosulphate
3'-phosphoadenosine 5'-phosphosulphate
3'-phosphoadenylyl sulphate
5'-o-[(r)-hydroxy(sulfooxy)phosphoryl]adenosine 3'-(dihydrogen phosphate)
DTXSID40894869
3'-phosphoadenosine 5'-phosphosulfate; [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methyl sulfo hydrogen phosphate
(((2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl)methyl phosphoric) sulfuric anhydride
Q229811
AKOS040753428

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The oral bioavailability of the beta 2-adrenoceptor agonist salbutamol has been proposed to be stereoselective, presumably due to presystemic sulphate conjugation."( Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity.
Pesola, GR; Walle, T; Walle, UK, 1993
)
0.29
" It is present in the diet, and the hepatic and duodenal sulphation might limit the bioavailability of this compound."( Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum.
De Santi, C; Mosca, F; Pacifici, GM; Pietrabissa, A; Spisni, R, 2000
)
0.31
" However, Fe bioavailability in alkaline soils is low due to the decreased solubility of the ferric ions."( PAP/SAL1 retrograde signaling pathway modulates iron deficiency response in alkaline soils.
Armas, AM; Balparda, M; Gomez-Casati, DF; Pagani, MA, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
", 2 hr after dosing depleted 60 to 80% of hepatic PAPS."( Homeostasis of sulfate and 3'-phosphoadenosine 5'-phosphosulfate in rats after acetaminophen administration.
Kim, HJ; Klaassen, CD; Madhu, C; Rozman, P, 1992
)
0.28
" The time course of the decline in PAPS values after 600 mg acetaminophen/kg showed that PAPS concentrations reached a nadir 1 hr after dosing (40% of control values)."( Acetaminophen decreases adenosine 3'-phosphate 5'-phosphosulfate and uridine diphosphoglucuronic acid in rat liver.
Hazelton, GA; Hjelle, JJ; Klaassen, CD,
)
0.13
" At the higher dosage of harmol, phorone reduced the biliary excretion of harmol sulfate while increasing the biliary excretion of harmol glucuronide."( Effect of glutathione depletion on sulfate activation and sulfate ester formation in rats.
Gregus, Z; Howell, S; Klaassen, CD; White, C, 1988
)
0.27
" N-Acetyl-L-cysteine, L-2-oxothiazolidine-4-carboxylate or the L- or D-isomers of 2-methylthiazolidine-4-carboxylate were administered to male mice immediately after a hepatotoxic dosage of acetaminophen (5."( Effects of cysteine pro-drugs on acetaminophen-induced hepatotoxicity.
Hazelton, GA; Hjelle, JJ; Klaassen, CD, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
adenosine bisphosphate
acyl sulfate
purine ribonucleoside bisphosphateA nucleoside phosphate consisting of a purine base linked to a ribose sugar esterified with one phosphate group attached to each of two different hydroxy groups on the sugar.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (33)

PathwayProteinsCompounds
Sulfate/Sulfite Metabolism620
Androgen and Estrogen Metabolism1230
Sphingolipid Metabolism2335
17-beta Hydroxysteroid Dehydrogenase III Deficiency1230
Gaucher Disease2335
Globoid Cell Leukodystrophy2335
Metachromatic Leukodystrophy (MLD)2335
Tamoxifen Action Pathway1027
Fabry Disease2335
Krabbe Disease2335
Sulfite Oxidase Deficiency620
Aromatase Deficiency1230
Tamoxifen Metabolism Pathway1027
Acetaminophen Metabolism Pathway3016
Cysteine Biosynthesis1329
Sulfur Metabolism2833
Sulfur Metabolism (Butanesulfonate)2834
Sulfur Metabolism (Propanesulfonate)2834
Sulfur Metabolism (Ethanesulfonate)2834
Sulfur Metabolism (Isethionate)2834
Sulfur Metabolism (Methanesulfonate)2834
Flavone and Flavonol Biosynthesis627
Estrone Metabolism1622
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
Proteoglycan biosynthesis011
11p11.2 copy number variation syndrome216
Mycobacterium tuberculosis biological processes3962
Sulfur compound metabolism1929
Sulfate assimilation712
sulfate assimilation011
Sulfate assimilation and copper detoxification020
Biochemical pathways: part I0466
Tamoxifen metabolism013
Sulfation biotransformation reaction010

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, NUCLEOSIDE DIPHOSPHATE KINASEDictyostelium discoideumKd14.000014.000014.000014.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1998The Journal of biological chemistry, Oct-30, Volume: 273, Issue:44
3'-Phosphorylated nucleotides are tight binding inhibitors of nucleoside diphosphate kinase activity.
AID1811Experimentally measured binding affinity data derived from PDB1998The Journal of biological chemistry, Oct-30, Volume: 273, Issue:44
3'-Phosphorylated nucleotides are tight binding inhibitors of nucleoside diphosphate kinase activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (444)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990179 (40.32)18.7374
1990's117 (26.35)18.2507
2000's77 (17.34)29.6817
2010's52 (11.71)24.3611
2020's19 (4.28)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.77 (24.57)
Research Supply Index6.13 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index51.21 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews34 (7.41%)6.00%
Case Studies1 (0.22%)4.05%
Observational0 (0.00%)0.25%
Other424 (92.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]